Single-fraction 24 Gy prostate RT plus ADT shows early control in 30 patients

Among 30 men with unfavorable-risk prostate cancer, single-fraction 24 Gy RT plus ADT produced 100% two-year biochemical control without grade ≥3 toxicity.

KEY POINTS

  • This prospective, single-center Italian study evaluated 30 patients with unfavorable intermediate-risk (33%) or selected high-risk (67%) localized prostate cancer treated between June 2021 and July 2023. Median age was 77 years (IQR 74–80), and all patients completed the predefined two-year assessment, with a median follow-up of 36.8 months (range 24.0–48.4) at analysis. Eligibility excluded cT3b or higher disease, PSA >20 ng/mL, nodal or distant metastases, and baseline IPSS >15.
  • Treatment consisted of 24 Gy delivered in a single fraction to the prostate and seminal vesicles, using 10-MV flattening-filter-free VMAT with urethral sparing and a 2-mm isotropic PTV margin. Treatment accuracy was supported by CBCT and real-time electromagnetic prostate tracking, with standardized bowel preparation and bladder filling. Twenty-nine patients received ADT, with a median duration of 12 months (range 6–24 months), and all patients received prophylactic alpha-blockers. No elective pelvic nodal irradiation or rectal spacer was used.
  • No grade ≥3 genitourinary or gastrointestinal adverse events were observed, corresponding to an estimated rate of 0% (95% CI 0–11.6%). The cumulative incidence of grade 2 GU toxicity was 23% (7/30) and grade 2 GI toxicity was 7% (2/30). At the two-year assessment, point prevalence decreased to 10% for grade 2 GU toxicity and 3% for grade 2 GI toxicity, with urinary urgency, incontinence, incomplete bladder emptying, dysuria, and rectal bleeding among the reported symptoms. Most grade 2 events were transient, although one patient had persistent grade 2 GU toxicity.
  • Baseline urinary symptoms and bladder trigone dose were associated with subsequent GU toxicity. Longitudinal ordinal regression identified higher baseline IPSS (β=0.38; p=0.003) and greater bladder trigone D1cc (β=2.96; p=0.017) as significant predictors of urinary adverse events. Time since irradiation itself was not significantly associated with worsening toxicity (p=0.298). These findings suggest a possible contribution of focal bladder substructure exposure, but the small sample size and limited event count prevent establishing a validated trigone dose constraint.
  • Biochemical recurrence-free survival was 100% at two years (95% CI 88.4–100%), with no biochemical failures observed. Median PSA decreased from approximately 8.6 ng/mL at baseline to 0.1 ng/mL at 24 months, and scheduled multiparametric MRI identified no suspicious local recurrences. Among the 29 patients receiving ADT, 22 (76%) had recovered testosterone by two years, with a median recovery interval of 10 months after ADT completion. The favorable PSA results must be interpreted in the context of concurrent hormonal therapy and relatively short follow-up for prostate cancer.
  • Group-level patient-reported outcomes remained broadly stable, but individual deterioration was not uncommon. Mean longitudinal changes in urinary symptom scores were statistically significant for IPSS (p=0.044) and EORTC QLQ-PR25 urinary symptoms (p=0.011), although estimated average changes remained below minimal important difference thresholds. At two years, however, clinically meaningful deterioration at the individual level was reported by 37% on IPSS, 53% on PR25 urinary symptoms, 20% on PR25 bowel symptoms, and 40% on global quality-of-life assessments. Erectile-function outcomes were deferred because only approximately half the cohort completed the relevant questionnaire.
  • The absence of a comparison group is the principal limitation. All patients received highly controlled single-fraction treatment, nearly all received ADT, and baseline urinary symptom severity was restricted, making the results difficult to generalize to unselected patients. With only 30 patients, uncommon late toxicity cannot be reliably excluded, and two-year biochemical control does not establish durable disease control or noninferiority to established five-fraction SBRT regimens.

CLINICAL TAKEAWAY

Single-fraction 24 Gy external beam radiotherapy combined with ADT demonstrated encouraging early biochemical control and an acceptable observed toxicity profile in carefully selected patients with unfavorable-risk localized prostate cancer. However, the small noncomparative cohort, frequent individual-level urinary symptom deterioration, and influence of concurrent ADT mean that this approach remains investigational and requires longer follow-up and randomized comparison with standard multifraction SBRT.

SOURCE

Practical Radiation Oncology

Browse more research Suggest a correction